WT13 is currently being formulated as a topical lotion for treating skin infections and wounds, including those caused by Methicillin-resistant Staphylococcus aureus MRSA and other drug-resistant bacteria. Skin infections are among the most common diseases worldwide, placing an immense burden on global healthcare. In 2010, skin infection ranked 4th among all diseases for years lost due to disability (YLD). It is estimated that up to 70% of all people will suffer one or more skin diseases during their lifetime. The micro-organism responsible for the majority of skin infections is Staphylococcus aureus, of which over 60% are MRSA strains (known as “golden staph”).
WT13 is in pre-clinical development, and is anticipated to enter clinical trials soon.
Our team won’t rest until this new antibiotic is available to the many patients who desperately need it.
1121 East Broadway St, Suite 155, Missoula, MT 59802
Suite 6, 424 Burke Rd, Camberwell, Victoria 3124, Australia